跳至主要内容
临床试验/NCT01614431
NCT01614431已完成4 期

N Acetyl Cysteine Can Decrease the Progression of Renal Disease in Cystinosis Patients

University of Sao Paulo0 个研究点目标入组 23 人开始时间: 2011年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
23
主要终点
creatinine clearance

研究概览

简要总结

This study intends to verify the interference of N acetyl cysteine in the progression of chronic kidney disease in patients with Nephropathic Cystinosis.

详细描述

Patients with Nephropathic Cystinosis have an increased oxidative stress and go to end-stage renal disease, even when all steps of the treatment are done. Therefore, this study is conducted to verify the interference of the stress oxidative in the progression of the renal disease with the use of an oxidant drug, N acetyl cysteine (NAC). The investigators selected patients with good compliance of the treatment. In these patients the investigators evaluate the serum creatinine, creatinine clearance estimated by Schwartz Formula, cystatin C and a marker of oxidative stress, TBARS ( thiobarbituric acid substances). The variables are analyzed 6 months before the introduction of NAC and the three months after NAC.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Year 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • cystinosis patients age under 18 years with good compliance to the treatment with Chronic Kidney Disease 1 to 4 according to KDOQI

排除标准

  • patients with CKD stage 5

研究组 & 干预措施

N acetyl cysteine

Experimental

NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)

干预措施: N acetyl cysteine (Drug)

结局指标

主要结局

creatinine clearance

时间窗: change in creatinine clearance evaluated 6 months before , at baseline and after 3 months with NAC

creatinine clearance will be evaluate 6 months beforw and at baseline and after 3 months with NAC

cystatin c

时间窗: change in cystatin C from baseline and after 3 months with NAC

Cystinosis patients will be evaluated 6 months before and at baseline and after 3 months after the use of NAC

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Maria Helena Vaisbich

Clinical Professor

University of Sao Paulo

相似试验